Tourmaline Bio to Present at the Guggenheim Healthcare Talks | 6th Annual Biotechnology Conference
01 Fevereiro 2024 - 10:00AM
Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage
clinical biotechnology company developing transformative medicines
to dramatically improve the lives of patients with life-altering
immune and inflammatory diseases, today announced that Sandeep
Kulkarni, CEO, will present at the in the following investor
conference:
Guggenheim Healthcare Talks | 6th Annual
Biotechnology ConferenceFireside chat February 7, 2024 at
11:00am ET
A live webcast and replay will be under "Events
and Presentations" in the News & Investors section of the
Tourmaline Bio website at https://ir.tourmalinebio.com.
About Tourmaline Bio, Inc. Tourmaline
is a late-stage clinical biotechnology company driven by its
mission to develop transformative medicines that dramatically
improve the lives of patients with life-altering immune and
inflammatory diseases.
About TOUR006TOUR006 is a long-acting,
fully-human, anti-IL-6 monoclonal antibody with best-in-class
potential and differentiated properties including a naturally long
half-life, low immunogenicity, and high binding affinity to IL-6.
To date, TOUR006 has been studied in 448 participants, including
patients with autoimmune disorders, across six clinical trials.
Tourmaline is developing TOUR006 in TED and ASCVD as its first two
indications, with additional diseases under consideration.
Contact:
Meru AdvisorsLee M. Sternlstern@meruadvisors.com
Tourmaline Bio (NASDAQ:TRML)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Tourmaline Bio (NASDAQ:TRML)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024